Lexicon Pharmaceuticals, Inc.(LXRX)

$2.29—Earnings in 7d

Chart

Lexicon Pharmaceuticals, Inc.(LXRX)

NASDAQ

$2.29—Earnings in 7d

Chart Studio

LXRX(LXRX)

LXRX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.06

Aug 5, 2026 · Reports before open

Revenue Estimate

$4M

Analyst Sentiment

Wall St. Consensus

Hold

14 analysts·Moderate coverage

Score

5 Buy (36%)7 Hold (50%)2 Sell (14%)

Rating Breakdown

Strong Buy

00%

Buy

536%

Hold

750%

Sell

214%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$6.00

+162.0%

Consensus

$6.00

+162.0%

Bull

$6.00

+162.0%

12-Month Target Range14 analysts

$6.00$6.00$6.00

Current $2.29Consensus

Current Price

$2.29

Upside to Consensus

$3.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-47.20%

EPS—

FY2028

Rev+277.90%

EPS—

FY2029

Rev+30.51%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$38M	$20M	$76M	$99M	$108M
Low	$31M	$12M	$7M	$59M	$64M
High	$45M	$29M	$148M	$141M	$153M
EBITDA Avg	$-37M	$-19M	$-74M	$-96M	$-104M
Low	$-44M	$-28M	$-143M	$-136M	$-148M
High	$-30M	$-12M	$-7M	$-57M	$-62M
EBIT Avg	$-37M	$-20M	$-74M	$-96M	$-104M
Low	$-44M	$-28M	$-143M	$-137M	$-148M
High	$-30M	$-12M	$-7M	$-57M	$-62M
Net Income Avg	$-58M	$-70M	$-53M	$-11M	$-10M
Low	$-61M	$-78M	$-58M	$-17M	$-15M
High	$-54M	$-63M	$17M	$-5M	$-5M
EPS Avg	$-0.16	$-0.20	$-0.09	$-0.03	$-0.03
Low	$-0.17	$-0.21	$-0.16	$-0.05	$-0.04
High	$-0.15	$-0.17	$0.05	$-0.01	$-0.01
Analysts (Rev / EPS)	4 / 3	3 / 3	5 / 4	2 / 2	2 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$3M	$10M	$800,000	$850,000	$900,000	$900,000
Low	$3M	$10M	$800,000	$850,000	$900,000	$900,000
High	$3M	$10M	$800,000	$850,000	$900,000	$900,000
EBITDA Avg	$-3M	$-10M	$-772,942	$-821,251	$-869,560	$-869,560
Low	$-3M	$-10M	$-772,942	$-821,251	$-869,560	$-869,560
High	$-3M	$-10M	$-772,942	$-821,251	$-869,560	$-869,560
EBIT Avg	$-3M	$-10M	$-774,938	$-823,371	$-871,805	$-871,805
Low	$-3M	$-10M	$-774,938	$-823,371	$-871,805	$-871,805
High	$-3M	$-10M	$-774,938	$-823,371	$-871,805	$-871,805
Net Income Avg	$-24M	$-22M	$-24M	$-24M	$-20M	$-18M
Low	$-28M	$-22M	$-24M	$-24M	$-20M	$-18M
High	$-20M	$-22M	$-24M	$-24M	$-20M	$-18M
EPS Avg	$-0.06	$-0.05	$-0.06	$-0.06	$-0.05	$-0.04
Low	$-0.07	$-0.05	$-0.06	$-0.06	$-0.05	$-0.04
High	$-0.05	$-0.05	$-0.06	$-0.06	$-0.05	$-0.04
Analysts (Rev / EPS)	3 / 3	2 / 1	1 / 1	2 / 1	2 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Mar 12, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potential exists"

Target:$6.00

+252.5%from $1.70

Oct 18, 2024Leerink Partners

Lexicon Pharmaceuticals (LXRX) PT Raised to $6 at Leerink Partners

Target:$6.00

+198.5%from $2.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance